Cabotegravir/Rilpivirine

Phase IIb EMBRACE study demonstrates N6LS (VH109), administered every four months with monthly cabotegravir, successfully maintained viral suppression in 96% of participants receiving intravenous treatment.

Real-world data presented at CROI 2025 demonstrates zero HIV acquisitions and high persistence with Apretude (cabotegravir LA) for PrEP across diverse populations, reinforcing its effectiveness in HIV prevention.

The FDA has approved Cabenuva, the first long-acting injectable HIV treatment administered monthly, offering an alternative to daily pill regimens for patients with HIV.

GSK experienced a significant 51% decline in Arexvy RSV vaccine sales to £590 million in 2024, following restricted US recommendations limiting use to adults 75 and older.

Pharmacist Jay Holloway highlights single-tablet regimens and long-acting injectables like CABENUVA as key advancements improving HIV medication adherence and patient outcomes.